Previous Article | Next Article 
Journal of Virology, September 2000, p. 8299-8306, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

+ T-Lymphocyte Cytotoxicity against
Envelope-Expressing Target Cells Is Unique to the Alymphocytic State of
Bovine Leukemia Virus Infection in the Natural Host
Patric
Lundberg and
Gary A.
Splitter*
Department of Animal Health and Biomedical
Sciences, University of Wisconsin
Madison, Madison, Wisconsin
53706
Received 16 March 2000/Accepted 15 June 2000
 |
ABSTRACT |
Bovine leukemia virus (BLV) is a complex B-lymphotrophic
retrovirus of cattle and the causative agent of enzootic bovine
leukosis. Serum antibody in infected animals does not correlate with
protection from disease, yet only some animals develop severe disease.
While a cytotoxic T-lymphocyte response may be responsible for
directing BLV pathogenesis, this possibility has been left largely
unexplored, in part since the lack of readily established cytotoxic
target cells in cattle has hampered such studies. Using long-term
naturally infected alymphocytic (AL) cattle, we have established the
existence of cytotoxic T-lymphocyte response against BLV envelope
proteins (Env; gp51/gp30). In vitro-expanded peripheral blood
mononuclear (PBM) cell effector populations consisted mainly of

+ (>40%), CD4+ (>35%), and
CD8+ (>10%) T lymphocytes. Specific lysis of autologous
fibroblasts infected with recombinant vaccinia virus (rVV) delivering
the BLV env gene ranged from 30 to 65%. Depletion studies
indicated that 
+ and not CD8+ T cells
were responsible for the cytotoxicity against autologous rVVenv-expressing fibroblasts. Additionally, cultured
effector cells lysed rVVenv-expressing autologous
fibroblasts and rVVenv-expressing xenogeneic targets
similarly, suggesting a lack of genetic restricted killing.
Restimulation of effector populations increased the proportion of

+ T cells and concomitantly Env-specific cytolysis.
Interestingly, culture of cells from BLV-negative or persistently
lymphocytic cattle failed to elicit such cytotoxic responses or
increase in 
+ T-cell numbers. These results imply
that cytotoxic 
+ T lymphocytes from only AL cattle
recognize BLV Env without a requirement for classical major
histocompatibility complex interactions. It is known that

+ T lymphocytes are diverse and numerous in cattle,
and here we show that they may serve a surveillance role during natural
BLV infection.
 |
INTRODUCTION |
Bovine leukemia virus (BLV) is among
the most widespread livestock pathogens in the United States. A recent
comprehensive survey revealed that 89% of dairy operations in the
United States, and 41 to 47% of all dairy cattle, are infected with
BLV (25). Despite a continued effort to link immune
responses against BLV and development of the nonbenign states of
enzootic bovine leukosis (EBL) (i.e., persistent lymphocytic [PL]
state and tumor development), the role of cell-mediated immunity
remains enigmatic. Yet, the host must keep the number of BLV-positive
(BLV+) cells from accumulating, as two-thirds of infected
cattle remain in the benign alymphocytic (AL) state of infection. Due
to the protracted pathology of EBL in cattle, most investigations of BLV pathogenesis have been done in sheep. In contrast, we chose to
pursue the role of cellular cytotoxicity in the natural host, cattle.
Consequently, the extended latency of BLV dictated the use of a
cross-sectional study, comparing groups of cattle that had remained in
their state of infection for an extended period of time. This study was
designed to address whether the state of infection correlated with a
specific immune response.
In BLV investigations using sheep, proviral integration and an increase
in circulating CD8+ lymphocytes precede seroconversion
(60). In the sheep model, identification of specific CD4 and
CD8 T-cell epitopes (19) and protection against BLV
challenge (38, 39, 42) have been demonstrated after
rVVenv inoculation. Furthermore, peptide immunizations have
also been shown protective against BLV infection in sheep (24). The picture is less defined in cattle. While several
immunization studies in cattle have induced (2, 31) or
failed to produce (6, 48) protection, none of these studies
addressed the role of cellular cytotoxicity. Also, in cattle, class I
and class II BoLA haplotypes show some correlation with state of
infection (12, 32, 62, 64). However, an actual effector
population of cellular cytotoxicity against components of BLV has not
been identified in cattle.
A functional role of 
+ T cells in response to
pathogens in cattle is still poorly defined. 
+ T
lymphocytes in ruminants express a diverse repertoire of the T-cell
receptor (TcR) (22, 23), and ruminants have an unusually high number of 
+ cells in circulation as well as in
certain tissues (9). The possible connection between a

+ T-cell response and the ability of most
BLV-infected animals to avoid severe disease has not been addressed.

+ T cells have been shown to mount cytotoxic,
cytokine, and proliferative responses in several other viral
infections. Most relevant to the present study is herpes simplex virus
infection, where 
+ T cells have been shown to
directly recognize the gI protein (51) and also correlate
with protection (30, 51, 52). In addition,

+ T cells are notably activated in cytomegalovirus
(14), influenza virus (26), and Sendai virus
(37) infections and, importantly, in several bovine viral
infections such as those caused by bovine respiratory syncytial virus
(50), bovine herpesvirus 1 (47), and
foot-and-mouth disease virus (3). Activated

+ T cells are also evident during simian and human
immunodeficiency virus (SIV and HIV) infections, although their
presence does not necessarily correlate with protection
(63; reviewed in reference 41),
and activated 
+ T cells in SIV and HIV infections
also react to certain cells lines (17, 57; reviewed
in references 8 and 28).
Human T-lymphotropic virus type 1 (HTLV-1) is genetically and
structurally closely related to BLV. However, the immune responses to
these viruses may require separate consideration, as no report links
(HTLV-1) and 
+ T-cell responses. First, HTLV-1
infects T cells in humans, while BLV infects B cells in cattle.
Inherently, the potential for affecting the immune system varies when a
different lymphocyte population is the major target for infection.
Second, the 
-TcR repertoire in cattle is much greater than in
humans (23), allowing for a more diversified

+ T-cell response in cattle.
Here, we test the hypothesis that AL cattle possess lymphocytes
capable of lysing cells expressing BLV antigen. The results demonstrate
that cytotoxic 
+ T lymphocytes of the natural
host, cattle, recognize both autologous and xenogeneic target cells
expressing BLV env but not irrelevant viral antigen (wild-type vaccinia
virus). Additionally, this response is not seen in cattle that are BLV
negative (BLV
) or PL, suggesting that these

+ cytotoxic T lymphocytes (CTLs) are intimately
connected to BLV pathogenesis.
 |
MATERIALS AND METHODS |
Classification of BLV
and AL animals.
Delineation between infectious states of naturally BLV-infected cattle
used previously established criteria (1) of total white
blood cell (WBC) counts and agar gel immunodiffusion (AGID) analysis.
Four BLV
, five BLV+ AL, and five
BLV+ PL adult cattle used in this investigation are listed
in Table 1. Briefly, BLV
cattle were free of serum antibody to BLV and had no integrated provirus as seen by PCR of the pol gene (4). AL
cattle were seropositive and carried BLV provirus. In contrast to AL
animals, which had WBC and B-cell counts similar to those of
BLV
animals, PL animals had elevated numbers of WBC and
circulating B cells. All BLV+ cattle had remained unchanged
in status for 5 to 8 years.
Flow cytometry for surface markers.
Briefly, mouse
monoclonal antibodies (MAbs) specific to bovine surface markers were
incubated with 106 cells for 90 min at room temperature.
Cells were washed three times with phosphate-buffered saline (PBS) and
incubated with fluorescein isothiocyanate-conjugated goat anti-mouse
immunoglobulin G (IgG; heavy plus light chain) for 90 min at room
temperature. Cells were washed three times with PBS, fixed in 1%
paraformaldehyde in PBS, and analyzed on an EPICS Profile II (Coulter
Corp., Miami, Fla.) within 5 days. Antibodies to CD2 (ILA42), CD4
(ILA11), CD8 (ILA51), and IgM (ILA30) (27), from the
American Type Culture Collection (Manassas, Va.), and 
-TcR1
subset (86D) (33), from the European Collection of Animal
Cell Culture (Salisbury, United Kingdom), were produced from purchased
hybridomas, while the pan-
-TcR MAb GD3.8 (61) was
kindly provided by the laboratory of Mark Jutila (Bozeman, Mont.). Both
86D, which recognizes an external epitope, and GD3.8 
-specific
antibodies immunoprecipitate 38- and 40-kDa peptides, supporting TcR1
specificity. Another CD8 MAb (38-65) from the First International
Antibody Workshop (27) was available in our lab. Two-color
flow cytometry was performed similarly, with the addition of a 20-min
preincubation with Fc Block (PharMingen, San Diego, Calif.) to
eliminate interference from Fc receptor expression.
Biotinylated MAbs were added at preoptimized concentrations followed by
strepavidin-phycoerythrin conjugate. Cells were analyzed the same day
or fixed in 1% paraformaldehyde and analyzed within 5 days.
Cell culture of hybridomas, target cell lines, PBM cells, and
autologous fibroblast lines.
All cells were maintained in complete
RPMI 1640 (cRPMI) supplemented with either 5% (cRPMI-5) or 10%
(cRPMI-10) fetal calf serum (FBS; Sigma, St. Louis, Mo.). Before use,
each lot of serum was verified free of detectable anti-BLV antibody by
the AGID assay. Hybridomas were grown in cRPMI-5. Peripheral blood
mononuclear (PBM) cells were isolated and cultured as described below
("Effector cell expansion protocol"). Primary autologous fibroblast
cultures used for target cells were established from skin biopsies of
each AL and BLV
animal studied and were either used
directly or frozen at
70°C in 10% dimethyl sulfoxide in FBS.
Briefly, minced skin sections were cultured for 10 to 14 days, and
outwardly migrating fibroblasts were collected for an initial expansion
of three to four passages, at which point aliquots were frozen in
liquid nitrogen to allow for retrieval of early passages. In general,
fibroblasts could be passaged more than 30 times before senescence
(approximately 100 generations). D17 cells (canine osteosarcoma;
obtained from the lab of Howard Temin) were maintained in cRPMI-5.
Recombinant and wild-type vaccinia virus preparation.
Wild-type vaccinia virus and recombinant vaccinia virus expressing the
BLV env gene (rVVenv) were kindly provided by
Misao Onuma (39) and Virogenetics, Inc. (Troy, N.Y.). New
viral working stocks were produced by infecting a monolayer of Vero
cells with the original virus preparations at a multiplicity of
infection of 2 and culturing the cells in cRPMI-10 for 5 days. The
infected cells were pelleted for 10 min at 250 × g in
a preparative centrifuge, and the pellet was freeze-thawed three times.
Prior to use, viral stocks were trypsinized for 30 min at 37°C. Viral
titer was determined using a standard plaque assay. Tenfold
dilutions of vaccinia virus were added to monolayers of either Vero
cells or autologous fibroblasts in cRPMI without FBS for 2 h. An
equal volume of cRPMI-10 was then added to each well, and the
plates were incubated for 3 to 4 days; then the culture medium was
removed, and the cells were stained with 1% crystal violet (Roboz
Surgical Instrument Co., Washington, D.C.). Similar PFU for a given
virus preparation were observed with Vero cells or autologous
fibroblasts (data not shown). Viral stocks were kept at 4°C or frozen
at
70°C, depending on length of storage before use.
Effector cell expansion protocol.
Heparinized blood was
obtained by jugular venipuncture from normal and infected adult
Holstein females. PBM cells were isolated over IsoPrep (Robbins
Scientific, Bloomington, N.J.) at 1,400 × g for 30 min, washed three times with PBS, resuspended in 25 ml of cRPMI-10, and
incubated at 1 × 106 to 2 × 106/ml
for 2 h in a 162-cm2 tissue culture flask. Adherent
cells were then discarded; nonadherent cells were transferred to a
standing 75-cm2 tissue culture flask and incubated for 3 days, after which 25 ml of cRPMI-10 with 50 U of recombinant human
interleukin-2 (rhIL-2) per ml was added. Expansion was continued for 7 to 9 days; then viable cells were isolated over IsoPrep and used in
cytotoxicity assays. Short-term cell lines were restimulated on a
similar culture cycle. Briefly, viable cells were isolated from the
expansion culture and combined with autologous irradiated PBM cells
(3,500 rad) for 2 to 3 days; then rhIL-2 (25 U/ml; half the
concentration used in the initial expansion) was added for
another 7 to 9 days. Lines remained viable in sufficient numbers
for use in assays for four to six cycles of restimulation. Although
IL-12 can elicit 
+ T cells, we have shown that
macrophages from AL animals produce prostaglandin E2, which
can inhibit in vitro expansion of 
+ T cells
(46).
Cytotoxicity assays.
Autologous fibroblasts, uninfected or
infected with vaccinia virus vectors (multiplicity of infection of 5)
for 12 to 18 h, were trypsinized, rinsed, and labeled with 1 µCi
of Na51CrO4 per 2,000 cells in cRPMI for 45 min. As target cells, autologous fibroblasts and D17 cells were >95
and 99% viable (by trypan blue exclusion), respectively, at 36 h
of infection (data not shown). Using immunofluorescence,
rVVenv-infected cells were approximately 80% positive for
vaccinia virus antigen 12 h postinfection (data not shown). After
labeling, targets were washed three times with PBS and resuspended in
cRPMI-10; then 5,000 cells were added per well in 96-well plates
for the assay. Gradient-purified effector cells were
added at various effector-to-target (E:T) ratios, with a final
volume of 200 µl. Plates were spun for 3 min at 150 × g before and after the 6-h assay. Supernatants were transferred to
tubes and counted using a gamma counter.
Depletion of CD8+ and 
+ T cells
from the effector population.
Using MAbs to CD8, CD4, and

-TcR, specific subpopulations were depleted by complement lysis
or two rounds of panning as adapted from previously published protocols
(16, 34). Briefly, complement lysis was accomplished by
incubating the population with a preoptimized amount of MAb on ice for
1 h in cRPMI. A final volume of 33% rabbit complement (Cedarlane,
Hornby, Ontario, Canada) was added, and incubation continued with
rotation for 1 h at 37°C; then cell debris was allowed to settle
for 5 min on ice. Suspended cells were washed three times in cRPMI and
adjusted to desired concentrations in cRPMI-10. Alternatively, plastic
culture dishes were coated with MAb diluted in PBS with 1% bovine
serum albumin at 4°C overnight and were washed five times with PBS
before use. Cells were allowed to adhere to the plate for 1 h at
room temperature. Nonadherent cells were transferred to a second plate,
and the incubation was repeated. CD8 and CD4 depletions were done by
complement lysis (MAb 38-65 [IgG2a] and ILA11 [IgG2a],
respectively) and depletions by two rounds of panning (MAb 86D
[IgG1]). Following depletions, the remaining cells were washed three
times and resuspended to the original volume with cRPMI-10.
 |
RESULTS |

+ T-lymphocyte expansion from PBM cells is unique
to AL animals.
Because the majority of BLV-infected cattle remain
in the benign AL state of infection, BLV-specific T cells may limit
viral infection. To address the hypothesis that antigen-reactive
effector cells could be expanded from BLV+ but not
BLV
animals, PBM cells were cultured in vitro. T-cell
proliferation is composed of two phases, antigen-specific activation
resulting in up-regulated IL-2 receptor expression followed by
IL-2-dependent expansion of activated cells (5). The
distribution of phenotypes of freshly isolated and cultured populations
from BLV
, AL, and PL cattle is shown in Table
2. Preexpansion cell populations were
similar in both AL and BLV
animals, although AL animals
had more CD4+ and CD2+ cells than either
BLV
or PL animals. Further analysis of these CD markers
was not done. PL cattle showed the symptomatic increase in B cells.
However, following the 10- to 12-day expansion in the presence of
endogenously expressed BLV and rhIL-2, AL animals had a significantly
higher proportion of 
+ T lymphocytes than either
BLV
(P < 0.001) or PL (P < 0.001) animals, suggesting that activation of T cells by BLV
followed by IL-2 expansion of antigen-specific T cells occurs
preferentially in the cells from AL animals. The postexpansion
cultures from BLV
and PL cattle did not contain
statistically different numbers of 
+ T cells
(P > 0.025). While the relative numbers of
CD4+ cells also increased slightly in all groups, the
proportion of CD8+ cells in AL animals decreased in
contrast to both BLV
(P < 0.001) and PL
animals (P < 0.001). Typically, expansion of cells
from BLV-free cattle yielded few viable cells, presumably due to the
lack of antigen-specific stimulation during the first 3 days of in
vitro culture.
In vitro expansion of AL PBM cells yields an Env-reactive cytotoxic
population.
To examine the function of the expanded cell
populations, autologous fibroblasts were used as targets to assess
cytotoxic ability. Expression of rVVenv in target cells was
confirmed by intracellular immunofluorescence and Western blot analysis
using polyclonal anti-vaccinia virus serum and anti-gp51 MAbs,
respectively (data not shown). Cytolytic activity against autologous
fibroblasts infected with rVVenv but not against wild-type
vaccinia virus was detected in expanded populations from AL animals
(Fig. 1A). In seven different experiments
with five different AL animals and three BLV
animals, the
Env-specific lysis by cells from AL animals ranged from 30 to 65%,
while cells from uninfected animals failed to lyse the target cells
(less than 5%). Despite the expansion of mainly CD8+ T
cells from BLV
animals on three occasions (Table 2),
those effectors were not able to lyse rVVenv-expressing
autologous fibroblasts (Fig. 1B).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Cytotolysis of rVVenv-expressing autologous
fibroblasts by expanded PBM cells from AL animal 17 (A) and
BLV animal 4205 (B). Targets were either infected with
rVVenv (triangles) or wild-type vaccinia virus (circles) or
uninfected (squares) in a 6-h 51Cr release assay.
Spontaneous release was less than 30%, and all determinations were
performed in triplicate. The data are representative of seven
experiments with three different AL animals and two different
BLV animals. Standard deviations were less than 5% for
all data points.
|
|
Depletion of 
+, but not CD8+ and
CD4+, T lymphocytes reduces Env-specific lysis in AL
animals.
To determine the T-lymphocyte population responsible for
the observed lysis, CD8+ and/or 
+ T
lymphocytes were depleted in the postexpansion effector populations. A
reduction of cytotoxicity resulted when 
+ cells were
removed (Fig. 2). Treatment with MAb 86D,
which recognizes 50 to 70% of 
+ T cells in the
expanded populations, caused an approximate 50% reduction in lysis of
env-expressing target cells, suggesting the involvement of

+ T cells. Depletion of CD8+ T cells or
CD4+ and CD8+ T cells, to remove the 
-TcR
population and address the role of 
-TcR cells in BLV
cytotoxicity, did not alter Env-specific lysis (Fig. 2). Thus,
BLV-infected animals in the AL state of infection possess

+ T cells that lyse env-expressing target
cells, while BLV
animals did not have detectable
cytotoxic 
+ T cells.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 2.
Cytotolysis of rVVenv-expressing autologous
fibroblasts by expanded PBM cell subsets from two AL animals, 17 (A)
and 201 (B). The assay was performed as for Fig. 1, at E:T
ratios of 50:1 (A) and 30:1 (B). Target cells were either
infected with rVVenv (filled) or wild-type vaccinia virus
(hatched) or uninfected (clear). Spontaneous release was less than
30%, and all determinations were performed in triplicate. The data are
representative of two experiments with two different AL animals. See
Materials and Methods for depletion protocols.
|
|
Expanded AL effectors are not classically MHC restricted.
Previously, NK-like cell lines from cattle (40) were shown
to lyse bovine herpesvirus 1-infected D17 cells (a canine osteosarcoma cell line). The vast majority of cells in that study were

+ T cells, which prompted us to test the
cytolytic activity of the AL-derived effectors against several common
target cell lines. Effectors expanded from AL animals would not
kill K562, YAC-1, Daudi, Vero, NMU, or COLO cells (data not
shown). However, similar to autologous fibroblasts (Fig. 1), D17 cells
were also lysed by AL-derived effector cells when infected with
rVVenv (Fig. 3). Minimal lysis
of wild-type vaccinia virus-infected and uninfected D17 cells was noted
at the highest E:T ratio (<10% specific lysis). The phenotypic
distribution of the effector populations used in Fig. 3 are shown in
Table 3. The use of D17 cells
consequently allows comparison of animals in different states of
infection using a single target population, while focusing the
examination on major histocompatibility complex
(MHC)-nonrestricted cytotoxicity. Thus, as expected, cytolytic

+ T cells from BLV-infected animals in the AL state
are not classically MHC restricted. Interestingly, PL animals possess
higher numbers of BLV-producing cells in vivo (18), and in
vitro demonstration of BLV antigens is much enhanced using cells from
PL animals compared to AL animals (15). Therefore, based on
BLV antigen availability in culture, 
+ T-cell
expansion and cytotoxicity should be greater in cells from PL animals.
This outcome was not observed in Table 2 and Fig. 3, suggesting only
cytotoxic 
+ T cells from AL animals recognize BLV
Env.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Cytotolysis of rVVenv-expressing D17 cells by
short-term cell lines (culture and one restimulation) from AL animal 17 (A), PL animal 2 (B), and BLV animal 602 (C). Targets
were either uninfected (squares) or infected with wild-type vaccinia
virus (circles) or rVVenv (triangles) and used in a 6-h
51Cr release assay. Spontaneous release was less than 30%,
and all determinations were performed in triplicate. The data are
representative of two experiments with two different AL animals, two
different BLV animals, and three different PL animals.
Standard deviations were less than 5% for all data points.
|
|
Restimulated AL cell lines retain their ability to lyse
rVVenv-expressing targets.
Since culture of PBM cells
from AL animals evoked a cytotoxic effector population, the
cultured cells were restimulated to assess continued antigen
specificity and enrichment for cytotoxicity. Indeed, Fig.
4 shows that short-term
cell lines were capable of substantial (50 to 100%) lysis after
three to four rounds of restimulation. Although individual cultures
varied in their relative lysis of rVVenv and wild-type
vaccinia virus-infected targets, specific cytotoxicity remained high
with continued in vitro culture (Fig. 4).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Env-specific lysis of rVVenv-infected D17
cells by short-term T-cell lines from animal 201. Lines were
restimulated three to four times with irradiated PBM cells and 25 U of
rhIL-2 per ml after initial expansion culture ( nx).
Independently derived 3-week cultures are given the letters A, B, and
C. D17 cells were infected with either rVVenv (solid) or
wild-type vaccinia virus (hatched). Spontaneous release was less than
35%, and determinations were done in triplicate at an E:T ratio of
20:1. The data are representative of two restimulation experiments for
this animal.
|
|
Cell lines from AL animals are unique in their lysis of
rVVenv-expressing targets.
To test whether in vitro
restimulation results in cytotoxic 
+ T cells
regardless of state of infection, cell lines from animals in all three
categories were tested for cytotoxic ability. Figure 5 shows that restimulated AL-derived cell
lines lysed rVVenv-expressing D17 cells, while cell lines
from BLV
and PL animals did not (Fig. 5). Cells from one
AL animal (animal 4) rarely lysed rVVenv-expressing targets
after initial PBM cell expansion. However, following repeated
restimulation, cells from this AL animal also showed high
env-specific lysis (Fig. 6).
Therefore, cattle in the AL state of infection possess cells capable of
lysing cells that express a BLV antigen; in contrast, animals in the PL
state of infection, as well as uninfected animals, do not have cytotoxic cells specific for BLV antigens.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
rVVenv-specific lysis of D17 target cells by
restimulated lines from AL but not from BLV or PL
animals. Lines were restimulated one to four times with irradiated PBM
cells and 25 U of rhIL-2 per ml after initial expansion culture. D17
cells were infected with either rVVenv (solid) or wild-type
vaccinia virus (hatched). Two BLV (A, 920-3x; B, 920-2x),
seven AL (C, 4-4x; D, 17-4x; E, 17-3x; F, 17-2x; G, 201-2x; H, 201-1x;
I, 234-1x), and seven PL (J, 019-3x; K, 019-2x; L, 019-1x; M, 2-3x; N,
2-1x; O, 191-3x; P, 191-1x) cell lines were used. The cell lines are
representative of a larger pool tested, and sequential numbers do not
necessarily refer to a continuous restimulation culture. Spontaneous
release was less than 30%, and determinations were done in triplicate
at an E:T ratio of 30:1. The data are representative of two
restimulation experiments.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 6.
rVVenv-specific lysis of D17 target cells by
restimulated lines from AL animal 4 despite insignificant lysis after
first culture. Effector populations were either cultured once from PBM
cells (cultured) or subsequently restimulated two (4-2x) or four (4-4x)
times with irradiated PBM cells and 25 U of rhIL-2 per ml after initial
culture. D17 cells were infected with either rVVenv (solid)
or wild-type vaccinia virus (hatched). Spontaneous release was less
than 25%, and determinations were done in triplicate at an E:T ratio
of 20:1.
|
|

+ T cells in restimulated AL cell lines increase
in relative number and correlate with cytotoxicity.
Because others
have observed an increase in CD2

+ T
cells in BLV+ cattle (54), and the expanded

+ cells from AL animals may be CD2
(Table 2), we determined if cells of this phenotype from AL animals
were expanded. The phenotypes of cell lines restimulated one to five
times (Table 4) were compared for their
cytotoxic potential (Fig. 7A). Increasing
numbers of 
+ T cells correlated with the level of
cytotoxicity. Conversely, the number of CD8+ T cells
declined more than 6-fold (Table 4), while env cytotoxicity increased nearly 10-fold (Fig. 7A). Additionally, when we determined the coexpression of CD2 and the 
-TcR, a correlation between increased cytotoxicity and the number of 
+ T cells
that were CD2
was equally striking (Fig. 7B), suggesting
the phenotype of the cytotoxic cell is 
+
CD2
. Similar findings between CD2

+ T cells and increasing cytotoxicity were evident
for long-term-cultured cell lines from two other AL animals. The
findings from this experiment further support the role of

+ T cells from the AL state of infection are
responsible for in vitro lysis of cells expressing a BLV antigen.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Cytotoxic activity against rVVenv-infected
D17 cells correlated with CD2  + T cells
in cell lines. Short-term cell lines from animal 17 (17-1x, 17-2x,
17-3x, and 17-4x) were restimulated with irradiated PBM cells one, two,
three, and four times, respectively. For flow cytometry data on these
lines, see Table 4. These are the aggregate data on sequential
restimulations of the same culture. (A) Increase in cytolytic activity
against rVVenv-infected (filled) but not wild-type vaccinia
virus-infected (hatched) D17 cells with each restimulation. Spontaneous
release was less than 30%, and determinations were done in triplicate
at an E:T ratio of 20:1. (B) Increase in percent CD2
 + T cells of total  + T cells with
each restimulation.
|
|
 |
DISCUSSION |
BLV is among the most persistent pathogens in cattle, whose immune
system, like that of all ruminants, is unique in its

+ T-cell prevalence and diversity. Despite these two
distinct phenomena, the relevance of 
+ T cells to BLV
pathogenesis has not been thoroughly explored. To address this lack of
understanding, we determined if 
+ T cells from
BLV-infected animals could recognize cells expressing components of
BLV. A large proportion of the expanded effector cell population from
adult AL animals were 
-TcR positive. These 
+ T
cells were cytotoxic to rVVenv-expressing target cells. In contrast to the AL animals, PBM cells from BLV
animals
typically failed to survive in parallel cultures. Only approximately
1/10 of the number of the cells survived in 3 of 8 attempted
BLV
cultures, compared to the constant recovery of cells
from each of 10 AL and 10 PL cultures (Table 2). Furthermore, cultures from PL animals contained approximately equal numbers of B cells, CD4+ T cells, and CD8+ T cells, all being
threefold more prevalent than 
+ T cells, and these
PL-derived effectors failed to lyse rVVenv-expressing target cells.
The role of 
+ T cells in ruminants may extend beyond
the proposed role of complementing 
+ T cells
suggested for primates (58). The prominence of

+ T cells in our in vitro studies and the high
proficiency of BLV-specific CTL activity suggests that

+ CTL play a significant role in controlling BLV
infection in the AL state. The lack of this reactive

+ CTL population in PL animals implies that

+ T cells are intimately connected to BLV
pathogenesis. To our knowledge, this is the first time that

+ T cells have been shown to respond specifically to
retroviral proteins in ruminants.
Depletion of CD8+, CD4+, and

+ cells indicated that 
+ cells
expanded from AL animals were largely responsible for the target cell
lysis. Additionally, the cytotoxicity to Env was not MHC restricted, as
evidenced by the lysis of rVVenv-infected D17 cells (Fig.
3). However, expanded PBM cells from AL cattle typically showed no
significant cytotoxicity against noninfected and wild-type vaccinia
virus-infected autologous target cells, indicating that the
cytotoxicity was not the result of NK cells. Cultured cells from AL
animals also contained a large proportion of CD4+ T
lymphocytes, while CD8+ T lymphocytes comprised less than a
third of the 
+ T-lymphocyte population. While the 10 to 20% CD8+ T lymphocytes may be responsible for the high
levels of cytotoxicity observed, depletion of CD8+ effector
cells did not alter cytotoxicity (Fig. 2), and reduction in
CD8+ cells occurred while cytotoxicity increased in the
short-term cell lines (Table 4 and Fig. 7). Also, the substantially
higher levels of CD8+ T cells in BLV
and PL
cattle following culture was not accompanied by increased cytotoxicity
(Fig. 3, Fig. 5, and data not shown). The relatively large proportion
(>35%) of CD4+ T lymphocytes in expanded cultures from AL
animals would be additional candidates for cytotoxic effector cells.
However, CD4+ CTLs are MHC class II restricted (reviewed in
reference 21), while autologous fibroblast targets
are MHC class II negative and D17 cells are xenogeneic to cattle.
Recently, 
+ T cells were reported to present antigen
and stimulate CD4+ cells (10). This possiblity
would explain the continued presence of CD4+ cells in our
cultures (Tables 2 to 4). Alternatively, there may be a reciprocal
relationship between CD4+ and 
+ cells
that is required for 
+ cell expansion and/or
cytotoxicity. Also, CD4+ cells may be stimulated
nonspecifically in culture through the presence of endogenous IL-2 or
other cytokines. Although investigation regarding the continued
CD4+ T-cell presence in culture was beyond the scope of
this study, depletion of CD4+ T cells did not affect
cytotoxicity in our system (Fig. 2); moreover, despite large
proportions (26 to 61%) of CD4+ cells in cell lines from
BLV
and PL animals, these effector populations were not
cytotoxic (Table 3, Fig. 3, and data not shown).
Since CD4+ and CD8+ cells are primarily
CD2+, the single surface marker staining in Table 2
suggests that cultured cells from AL animals increase in

+ cells but not in CD2+ cells.
Additionally, CD2

+ cells increase in
BLV+ cattle (54), and we show here that loss of
CD2 expression on 
+ T cells correlated with
restimulation of effector cells concomitantly with increased
cytotoxicity (Table 4 and Fig. 7). However, decreasing CD2+
cells over time may be a consequence of CD2-mediated apoptosis (55). Future experiments should address the relevance of
this 
+ subpopulation in the
rVVenv-specific cytotoxic response. In all cytotoxicity
assays, the relative numbers of 
cell subsets, TcR-N3, TcR-N4,
TcR-N6, TcR-N7, TcR-N12 (13), and 86D, were determined, but
none of these populations demonstrated a correlation with BLV infection
status or cytotoxicity in cultured cell populations (data not shown).
The exclusive role for 
+ CTLs is corroborated by the
lysis of D17 targets expressing BLV proteins, where a conventional
coreceptor model cannot explain the data. While an apparent lack of MHC
restriction was observed, nonclassical presentation molecules (such as
CD1) cannot be excluded. However, recognition of nonclassical MHC
molecules by bovine 
+-TcR has not been shown to date
and may be an unlikely explanation.
Occasionally, AL animals in this study had slightly elevated levels of
circulating 
+ cells relative to noninfected control
animals, but the increase was not statistically significant (Table 2).
However, the BLV
animals used in this study had a
slightly higher number of circulating 
+ cells than
previously reported (18), possibly due to the lack of a
specific pan-
-TcR MAb in the earlier study.
Considering that BLV mRNA can be detected ex vivo in sheep
(43), the immune system of infected cattle may encounter BLV antigen with relative frequency despite the extended latency of BLV in
cattle. Indeed, individual cells of cattle have been shown to express
BLV mRNA in vivo (20). In the sheep model, periodic appearance of Rex-specific antibodies and sustained antibodies against
other BLV components was detected (43), implying opportunity for repeated contact with BLV antigen and repeated stimulation of
BLV-specific 
+ T cells. Although disease development
in cattle is not precisely mimicked by sheep, infected cattle similarly
remain seropositive and proviral DNA can be found throughout life.
Furthermore, endogenous BLV antigen is produced by B cells from cattle
during in vitro culture (references 1, 15, and
29 and data not shown), providing a source of BLV
antigen for 
+ T cells.
In HIV, V
9/V
2 T-cell responses to HIV-infected targets exist in
both uninfected and infected individuals (59), but these cells are diverse in the complementarity-determining region 3 of the
TcR and also recognize other virus-infected cells. We have no evidence
that the 
+ T cells identified in this study are
similarly limited in 
chain expression, but they recognize
neither wild-type vaccinia virus-infected targets nor any of several
common cell lines in our cytotoxicity assay. In HIV-negative humans,
V
9/V
2+ T cells recognize HIV- or SIV-infected cells
and Daudi cells without a requirement for prior activation
(7; reviewed in reference 57),
suggesting that antigen-specific stimulation may not be necessary for
antiretroviral activity. Additionally, V
9/V
2+ T cells
from HIV-positive individuals are functionally defective in the ability
to respond to stimulation by Daudi cells and ethyl pyrophosphate
(59). Similarly, in SIV, 
+ CTLs respond to
infected target cells and Daudi cells (17, 56). The extent
to which the 
+ T cells in HIV- or SIV-positive
primates parallel the PBM cells from BLV+ cattle remains to
be determined. Additionally, 
+ CTLs have not been
identified in individuals infected with HTLV-1, and the bovine

+ CTLs in the present study were unique to AL animals
and were not reactive to Daudi cells.
Often, CTL studies use a specific antigen derived from the pathogen of
interest, many times in the form of peptide-pulsed antigen-presenting
cells (APC). By necessity, peptide-pulsing studies select for a CTL
population capable of engaging APC surface molecules carrying the
administered peptide antigen. In contrast, the present study relied on
endogenous BLV as a source of antigen, followed by expansion of
antigen-responsive T lymphocytes in culture. Consequently, the antigen
presentation pathway is determined by natural viral expression during
effector stimulation. The presence of BLV antigen and reverse
transcriptase activity in culture supernatants from BLV-infected
animals in this study was confirmed but not quantified (data not
shown). Addition of rhIL-2 at the start of the in vitro culture or
omission of rhIL-2 during the 7- to 9-day expansion phase resulted in
high nonspecific or no cytotoxicity, respectively (data not shown). The
use of endogenous BLV as the antigen may more accurately represent the
role that BLV plays in vivo. The minimal manipulation of the cultured
PBM cells more likely representative than peptide-pulsed APC
stimulation in modeling what occurs as the integrated BLV provirus
breaks latency.
Aside from antigen availability during culture, correlation of the AL
and PL states of infection with BoLA haplotypes (12, 32, 62,
64) and cytokine profiles (36, 44-46, 54) suggests that immune responses from BLV+ animals are linked to
cytokine production. All PBM cell cultures from BLV+
animals produce IL-10 over time (D. Pyeon, personal communication), and
macrophages from PL cattle also secrete significant amounts of IL-10 ex
vivo (45) whereas macrophages from AL animals secrete IL-12
(44). The combination of IL-2 and IL-12 has been found to
elicit highly reactive human 
+ CTLs (49).
Additionally, IL-12 and IL-1 are necessary for the development and
activation of 
+ responses (53). We know
from our previous work (reference 11 and data not
shown) that large quantities of IL-1 are present at early stages of in
vitro culture. Consequently, the choice between IL-10 and IL-12
production and/or secretion may help determine, or result from, the
infection state of EBL. Similarly, reactivity to Mycobacterium
tuberculosis (35) and HIV (7) by

+ T cells is enhanced by IL-12 and abrogated by IL-10
(35). Interestingly, the PBM cells from the less

+ T-cell-reactive AL animal 4 contained higher
baseline levels of IL-10 mRNA ex vivo than the more reactive AL animals
(Pyeon, personal communication). As shown in Fig. 6, restimulation of PBM cells from this animal and removal of macrophages as the source of
IL-10 in vitro (45) overcame an initial lack of a

+ T-cell response, indicating that unresponsiveness
was not permanent. However, under identical culture conditions, cells
from PL animals did not possess rVVenv-specific cytotoxicity
(Fig. 5). In conclusion, this study shows that AL cattle, but not PL
cattle, are capable of eliciting Env-specific 
+ CTLs.
These CTLs are not MHC restricted and may recognize the BLV protein
directly. Defining the role of this unique cell population from AL
animals could be crucial to understanding the pathology of EBL.
 |
ACKNOWLEDGMENTS |
We thank Virogenetics, Inc., and Misao Onuma for providing
samples of recombinant vaccinia virus. Thanks go to Oto Orlik for providing expert advice as well as anti-BLV MAbs, to Jerome Harms, David Pauza, and Paul Lambert for helpful discussions, and to Cathryn
Lundberg for assistance with the immunofluorescence. We are also
grateful for the generous supply of GD3.8 antibody from Mark Jutila.
This work was supported by National Cancer Institute grant ROI CA59127,
BARD 95-34339-2556, and the University of Wisconsin College of
Agricultural and Life Sciences.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Animal Health and Biomedical Sciences, University of
Wisconsin
Madison, 1655 Linden Dr., Madison, WI 53706. Phone: (608)
262-1837. Fax: (608) 262-7420. E-mail:
gas{at}ahabs.wisc.edu.
 |
REFERENCES |
| 1.
|
Adomaitiene, D.,
V. Tamosiunas,
M. Mauricas,
V. Surovas, and A. Markevicius.
1983.
Establishment of a cell line from leucocytes of a cow with chronic lymphocytic leukemia.
Vet. Immunol. Immunopathol.
4:565-577[CrossRef][Medline].
|
| 2.
|
Altaner, C.,
J. Ban,
V. Altanerova, and V. Janik.
1991.
Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine.
Vaccine
9:889-895[CrossRef][Medline].
|
| 3.
|
Amadori, M.,
I. L. Archetti,
R. Verardi, and C. Berneri.
1995.
Role of a distinct population of bovine T cells in the immune response to viral agents.
Viral Immunol.
8:81-91[Medline].
|
| 4.
|
Boris-Lawrie, K.,
V. Altanerova,
C. Altaner,
L. Kucerova, and H. Temin.
1997.
In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex.
J. Virol.
71:1514-1520[Abstract].
|
| 5.
|
Chain, B.,
I. McCafferty,
G. McCafferty,
G. Wallace, and P. W. Askenase.
1987.
Improvement of the in vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps.
J. Immunol. Methods
99:221-228[CrossRef][Medline].
|
| 6.
|
Cherney, T. M., and R. D. Schultz.
1996.
Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes.
Am. J. Vet. Res.
57:812-818[Medline].
|
| 7.
|
Chervenak, K. A.,
M. M. Lederman, and W. H. Boom.
1997.
Bacterial antigen activation of V +1 and V +2  T cells of persons infected with human immunodeficiency virus type 1.
J. Infect. Dis.
175:429-433[Medline].
|
| 8.
|
Chien, Y. H.,
R. Jores, and M. P. Crowley.
1996.
Recognition by / + T cells.
Annu. Rev. Immunol.
14:511-532[CrossRef][Medline].
|
| 9.
|
Ciccarese, S.,
C. Lanave, and C. Saccone.
1997.
Evolution of T-cell receptor gamma and delta constant region and other T-cell-related proteins in the human-rodent-artiodactyl triplet.
Genetics
145:409-419[Abstract].
|
| 10.
|
Collins, R. A.,
D. Werling,
S. E. Duggan,
A. P. Bland,
K. R. Parsons, and C. J. Howard.
1998.
 + T cells present antigen to CD4+  T cells.
J. Leukoc. Biol.
63:707-714[Abstract].
|
| 11.
|
Covert, J., and G. Splitter.
1995.
Detection of cytokine transcriptional profiles from bovine peripheral blood mononuclear cells and CD4+ lymphocytes by reverse transcriptase polymerase chain reaction.
Vet. Immunol. Immunopathol.
49:39-50[CrossRef][Medline].
|
| 12.
|
Da, Y.,
R. D. Shanks,
J. A. Stewart, and H. A. Lewin.
1993.
Milk and fat yields decline in bovine leukemia virus-infected dairy cattle with persistent lymphocytosis.
Proc. Natl. Acad. Sci. USA
94:6538-6541[CrossRef].
|
| 13.
|
Davis, W. C.,
W. C. Brown,
M. J. Hamilton,
C. R. Wyatt,
J. A. Orden,
A. M. Khalid, and J. Naessens.
1996.
Analysis of monoclonal antibodies specific for the gamma delta TcR.
Vet. Immunol. Immunopathol.
52:275-283[CrossRef][Medline].
|
| 14.
|
Dechanet, J.,
P. Merville,
A. Lim,
C. Retiere,
V. Pitard,
X. Lafarge,
S. Michelson,
C. Meric,
M. M. Hallet,
P. Kourilsky,
L. Potaux,
M. Bonneville, and J. F. Moreau.
1999.
Implication of  T cells in the human immune response to cytomegalovirus.
J. Clin. Investig.
103:1437-1449[Medline].
|
| 15.
|
Driscoll, D. M., and C. Olson.
1977.
Bovine leukemia virus-associated antigens in lymphocyte cultures.
Am. J. Vet. Res.
38:1897-1898[Medline].
|
| 16.
|
Falkoff, R. M.,
M. Peters, and A. S. Fauci.
1982.
T cell enrichment and depletion of human peripheral blood mononuclear cell preparations. Unexpected findings in the study of the separated populations.
J. Immunol. Methods
50:39-49[CrossRef][Medline].
|
| 17.
|
Gan, Y. H., and M. Malkovsky.
1996.
Mechanisms of simian gamma delta T cell cytotoxicity against tumor and immunodeficiency virus-infected cells.
Immunol. Lett.
49:191-196[CrossRef][Medline].
|
| 18.
|
Gatei, M. H.,
R. B. Brandon,
H. M. Naif,
M. W. McLennan,
R. C. Daniel, and M. F. Lavin.
1989.
Changes in B cell and T cell subsets in bovine leukaemia virus-infected cattle.
Vet. Immunol. Immunopathol.
23:139-147[CrossRef][Medline].
|
| 19.
|
Gatei, M. H.,
M. F. Good,
R. C. Daniel, and M. F. Lavin.
1993.
T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development.
J. Virol.
67:1796-1802[Abstract/Free Full Text].
|
| 20.
|
Gaynor, E. M.,
M. L. Mirsky, and H. A. Lewin.
1996.
Use of flow cytometry and RT-PCR for detecting gene expression by single cells.
BioTechniques
21:286-291[Medline].
|
| 21.
|
Hahn, S.,
R. Gehri, and P. Erb.
1995.
Mechanism and biological significance of CD4-mediated cytotoxicity.
Immunol. Rev.
146:57-79[CrossRef][Medline].
|
| 22.
|
Hein, W. R., and L. Dudler.
1993.
Divergent evolution of T cell repertoires: extensive diversity and developmentally regulated expression of the sheep  T cell receptor.
EMBO J.
12:715-724[Medline].
|
| 23.
|
Hein, W. R., and L. Dudler.
1997.
TcR gamma delta+ cells are prominent in normal bovine skin and express a diverse repertoire of antigen receptors.
Immunology
91:58-64[CrossRef][Medline].
|
| 24.
|
Hislop, A. D.,
M. F. Good,
L. Mateo,
J. Gardner,
M. H. Gatei,
R. C. Daniel,
B. V. Meyers,
M. F. Lavin, and A. Suhrbier.
1998.
Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge.
Nat. Med.
4:1193-1196[CrossRef][Medline].
|
| 25.
|
Hopkins, S. G., and R. F. DiGiacomo.
1997.
Natural transmission of bovine leukemia virus in dairy and beef cattle.
Vet. Clin. North Am. Food Anim. Pract.
13:107-128[Medline].
|
| 26.
|
Hoq, M. M.,
T. Suzitani,
T. Toyoda,
G. Horiike,
I. Yoshida, and M. Azuma.
1997.
Role of  TcR+ lymphocytes in the augmented resistance of trehalose 6,6'-dimycolate-treated mice to influenza virus infection.
J. Gen. Virol.
78:1597-1603[Abstract].
|
| 27.
|
Howard, C. J.,
W. I. Morrison,
W. R. Hein,
C. R. MacKay, and G. A. Splitter.
1991.
Leukocyte antigens in cattle, sheep and goats.
Vet. Immunol. Immunopathol.
27:1-276[CrossRef][Medline].
|
| 28.
|
Kaufmann, S. H.
1996.
 and other unconventional T lymphocytes: what do they see and what do they do?
Proc. Natl. Acad. Sci. USA
93:2272-2279[Abstract/Free Full Text].
|
| 29.
|
Kerkhofs, P.,
E. Adam,
L. Droogmans,
D. Portetelle,
M. Mammerickx,
A. Burny,
R. Kettman, and L. Willems.
1996.
Cellular pathways involved in the ex vivo expression of bovine leukemia virus.
J. Virol.
70:2170-2177[Abstract].
|
| 30.
|
Kodukula, P.,
T. Liu,
N. V. Rooijen,
M. J. Jager, and R. L. Hendricks.
1999.
Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system.
J. Immunol.
162:2895-2905[Abstract/Free Full Text].
|
| 31.
|
Kukaine, R. A.,
L. I. Nagayeva,
S. V. Chapenko,
T. N. Iljinskaya,
O. I. Bratsslvskaya,
L. A. Vitolin,
I. K. Yanchev,
S. Bozhkov,
I. I. Alexandrov,
R. N. Stefanova,
I. S. Florova,
B. Parvoulov,
M. I. Mateev, and N. Z. Sotirov.
1993.
Protection against bovine leukemia virus infection in two breeds of cattle.
Comp. Immunol. Microbiol. Infect. Dis.
16:63-71[CrossRef][Medline].
|
| 32.
|
Lewin, H. A.,
M. C. Wu,
J. A. Stewart, and T. J. Nolan.
1988.
Association between BoLA and subclinical bovine leukemia virus infection in a herd of Holstein-Friesian cows.
Immunogenetics
27:338-344[CrossRef][Medline].
|
| 33.
|
Mackay, C. R.,
M.-F. Beya, and P. Matzinger.
1989.
T cells express a unique surface molecule appearing late during thymic development.
Eur. J. Immunol.
19:1477-1488[Medline].
|
| 34.
|
Mage, M. G.
1994.
Fractionation of T cells and B cells, p. 3.5.1-3.5.6.
In
R. Coico (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
|
| 35.
|
Marx, S.,
D. Wesch, and D. Kabelitz.
1997.
Activation of human gamma delta T cells by Mycobacterium tuberculosis and Daudi lymphoma cells: differential regulatory effect of IL-10 and IL-12.
J. Immunol.
158:2842-2848[Abstract].
|
| 36.
|
Meirom, R.,
S. Moss,
J. Brenner,
D. Heller, and Z. Trainin.
1997.
Levels and role of cytokines in bovine leukemia virus (BLV) infection.
Leukemia
11(Suppl. 3):219-220.
|
| 37.
|
Ogasawara, T.,
M. Emoto,
K. Kiyotani,
K. Shimokata,
T. Yoshida,
Y. Nagai, and Y. Yoshikai.
1994.
Sendai virus pneumonia: evidence for the early recruitment of  T cells during the disease course.
J. Virol.
68:4022-4027[Abstract/Free Full Text].
|
| 38.
|
Ohishi, K.,
H. Suzuki,
T. Yamamoto,
T. Maruyama,
K. Miki,
Y. Ikawa,
S. Numakunai,
K. Okada,
K.-I. Ohshima, and M. Sugimoto.
1991.
Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with a vaccinia virus-BLV env recombinant: association with cell-mediated immunity.
J. Gen. Virol.
72:1887-1892[Abstract/Free Full Text].
|
| 39.
|
Onuma, M.,
T. Hodatsu,
S. Yamamoto,
M. Higashihara,
S. Masu,
T. Mikami, and H. Izawa.
1984.
Protection by vaccination against bovine leukemia virus infection in sheep.
Am. J. Vet. Res.
45:1212-1215[Medline].
|
| 40.
|
Palmer, L.,
T. Leary,
K. Wilson, and G. Splitter.
1990.
Bovine natural killer-like cell responses against cell lines expressing recombinant bovine herpesvirus type 1 glycoproteins.
J. Immunol.
145:1009-1014[Abstract].
|
| 41.
|
Poccia, F.,
M. Wallace,
V. Colizzi, and M. Malkovsky.
1998.
Possible protective and pathogenic roles of  T lymphocytes in HIV-infections.
Int. J. Mol. Med.
1:409-413[Medline].
|
| 42.
|
Portetelle, D.,
K. Limbach,
A. Burny,
M. Mammerickx,
P. Desmettre,
M. Riviere,
J. Zavada, and E. Paoletti.
1991.
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection.
Vaccine
9:194-200[CrossRef][Medline].
|
| 43.
|
Powers, M. A.,
D. Grossman,
L. C. Kidd, and K. Radke.
1991.
Episodic occurrence of antibodies against the bovine leukemia virus Rex protein during the course of infection in sheep.
J. Virol.
65:4959-4965[Abstract/Free Full Text].
|
| 44.
|
Pyeon, D., and G. A. Splitter.
1998.
Interleukin-12 p40 mRNA expression in bovine leukemia virus-infected animals: increased in alymphocytosis but decreased in persistent lymphocytosis.
J. Virol.
72:6917-6921[Abstract/Free Full Text].
|
| 45.
|
Pyeon, D.,
K. L. O'Reilly, and G. A. Splitter.
1996.
Increased interleukin-10 mRNA expression in tumor-bearing or persistently lymphocytotic animals infected with bovine leukemia virus.
J. Virol.
70:5706-5710[Abstract/Free Full Text].
|
| 46.
|
Pyeon, D.,
F. J. Diaz, and G. A. Splitter.
2000.
Prostaglandin E2 increases bovine leukemia virus tax and pol mRNA via cyclooxygenase-2: regulation by interleukin-1, interleukin-10, and bovine leukemia virus.
J. Virol.
74:5740-5745[Abstract/Free Full Text].
|
| 47.
|
Quade, M. J., and J. A. Roth.
1999.
Antigen-specific in vitro activation of T-lymphocyte subsets of cattle immunized with a modified live bovine herpesvirus 1 vaccine.
Viral Immunol.
12:9-21[Medline].
|
| 48.
|
Ristau, E.,
W. Wittman,
E. Starick, and K. H. Kluge.
1989.
Bovine leucosis virus challenge infection of calves following application of BL-3 cells.
Arch. Exp. Veterinaermed.
43:155-158[Medline].
|
| 49.
|
Satoh, M.,
S. Seki,
W. Hashimoto,
K. Ogasawara,
T. Kobayashi,
K. Kumagai,
S. Matsuno, and K. Takeda.
1996.
Cytotoxic prostaglandin  - or  -T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2.
J. Immunol.
157:3886-3892[Abstract].
|
| 50.
|
Schrijver, R. S.,
J. P. Langedijk,
G. M. Keil,
W. G. Middel,
M. Maris-Veldhuis,
J. T. Van Oirschot, and F. A. Rijsewijk.
1997.
Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV.
Vaccine
15:1908-1916[CrossRef][Medline].
|
| 51.
|
Sciammas, R., and J. A. Bluestone.
1998.
HSV-1 glycoprotein I-reactive TcR  cells directly recognize the peptide backbone in a conformationally dependent manner.
J. Immunol.
161:5187-5192[Abstract/Free Full Text].
|
| 52.
|
Sciammas, R.,
P. Kodukula,
Q. Tang,
R. L. Hendricks, and J. A. Bluestone.
1997.
T cell receptor- cells protect mice from herpes simplex virus type 1-induced lethal encephalitis.
J. Exp. Med.
185:1969-1975[Abstract/Free Full Text].
|
| 53.
|
Skeen, M. J., and H. K. Ziegler.
1995.
Activation of gamma delta T cells for production of IFN-gamma is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12.
J. Immunol.
154:5832-5841[Abstract].
|
| 54.
|
Sordillo, L. M.,
C. R. Hicks, and G. M. Pighetti.
1994.
Altered interleukin-2 production by lymphocyte populations from bovine leukemia virus-infected cattle.
Proc. Soc. Exp. Biol. Med.
207:268-273[CrossRef][Medline].
|
| 55.
|
Spinozzi, F.,
I. Nicoletti,
E. Agea,
S. Belia,
R. Moraca,
G. Migliorati,
C. Riccardi,
F. Grignani, and A. Bertotto.
1995.
IL-4 is able to reverse the CD2-mediated negative apoptotic signal to CD4-CD8- alpha beta and/or gamma delta T lymphocytes.
Immunology
86:379-384[Medline].
|
| 56.
|
Wallace, M.,
Y. H. Gan,
C. D. Pauza, and M. Malkovsky.
1994.
Antiviral activity of primate gamma delta T lymphocytes isolated by magnetic cell sorting.
J. Med. Primatol.
23:131-135[Medline].
|
| 57.
|
Wallace, M.,
M. Malkovsky, and S. R. Carding.
1995.
Gamma/delta T lymphocytes in viral infections.
J. Leukoc. Biol.
58:277-283[Abstract].
|
| 58.
|
Wallace, M.,
S. R. Bartz,
W. L. Chang,
D. A. Mackenzie,
C. D. Pauza, and M. Malkovsky.
1996.
Gamma delta T lymphocyte responses to HIV.
Clin. Exp. Immunol.
103:177-184[CrossRef][Medline].
|
| 59.
|
Wallace, M.,
A. M. Scharko,
C. D. Pauza,
P. Fisch,
K. Imaoka,
S. Kawabata,
K. Fujihashi,
H. Kiyono,
Y. Tanaka,
B. R. Bloom, and M. Malkovsky.
1997.
Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections.
Mol. Med.
3:60-71[Medline].
|
| 60.
|
Ward, W. H.,
C. K. Dimmock, and F. W. Eaves.
1992.
T lymphocyte responses of sheep to bovine leukaemia virus infection.
Immunol. Cell Biol.
70:329-336.
|
| 61.
|
Wilson, E.,
B. Walcheck,
W. C. Davis, and M. A. Jutila.
1998.
Preferential tissue localization of  T cell subsets defined by anti-T cell receptor antibodies.
Immunol. Lett.
64:39-44[CrossRef][Medline].
|
| 62.
|
Xu, A.,
M. J. T. Van Eijk,
C. Park, and H. A. Lewin.
1993.
Polymorphism of BoLA-DRB3 exon 2 correlates with resistance and susceptibility to persistent lymphocytosis caused by bovine leukemia virus.
J. Immunol.
151:6977-6986[Abstract].
|
| 63.
|
Yin, C.,
M. S. Wu,
C. D. Pauza, and M. S. Salvato.
1999.
High major histocompatibility complex-unrestricted lysis of simian immunodeficiency virus envelope-expressing cells predispose macaques to rapid AIDS progression.
J. Virol.
73:3692-3701[Abstract/Free Full Text].
|
| 64.
|
Zanotti, M.,
G. Poli,
W. Ponti,
M. Polli,
M. Rocchi,
E. Bolzani,
M. Longeri,
S. Russo,
H. A. Lewin, and M. J. van Eijk.
1996.
Association of BoLA class II haplotypes with subclinical progression of bovine leukaemia virus infection in Holstein-Friesian cattle.
Anim. Genet.
27:337-341[Medline].
|
Journal of Virology, September 2000, p. 8299-8306, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fulton, B. E. Jr., Portella, M., Radke, K.
(2006). Dissemination of bovine leukemia virus-infected cells from a newly infected sheep lymph node.. J. Virol.
80: 7873-7884
[Abstract]
[Full Text]